Pinned
Ben Liu
185 posts
Ben Liu
@BenjamineYLiu
co-founder and CEO @formationbio
- Excited to announce our $372MM Series D financing, led by @a16z with major participation from @sanofi. Existing + new investors @sequoia, @ThriveCapital, @lachygroom, @EmCollective, @svangel and @FPVventures also joined this round.endpts.com/with-a-372m-me… We are grateful to share
- Excited to announce our license of Gusacitinib to @sanofi for upwards of €545M in upfront and milestones in addition to royalties in the low to mid-teen based on future sales.
- Excited to share an update at @formationbio: We’ve added @IMIDomics first-in-class anti-CD226 antibody to our pipeline — a Phase 1–ready program for Ulcerative Colitis. Grateful to Fred Craves & Sandy Zweifach for the collaboration and shared vision for the program’s future.@IMIDomics discovered the initial science, and now @formationbio is taking it forward to clinical development. Today we announced our license of IMIDomics' first-in-class, Phase-1 ready anti-CD226 antibody targeting Ulcerative Colitis. Go behind the scenes with both teams here.00:00
- Replying to @davidycliHi David, don’t disagree with your core message. However, I do want to correct the record that @formationbio always planned to be a full stack Pharma company, differentiated by faster/more efficient clinical trials + drug development. In fact, this was articulated in our seed
- We are excited for TrialSpark to rebrand as @formationbio as we build the pharma company of the future that will accelerate the pace we bring new treatments to patients.
- Excited to welcome @skupor and @Alfred_Lin to our board of directors alongside existing board member @moritzKBE. We look forward to sharing the journey ahead!Few companies have expansive of a vision as does @formationbio - we are excited to become partners in this next phase of growth as the company tackles the drug development bottleneck bringing new medicines to market.a16z.com/announcement/i…
- Replying to @skupor @realDonaldTrump and 2 othersCongrats @skupor. The country is fortunate to have you serve in this role. Look forward to seeing all that you will accomplish!
- Excited about @formationbio's collaboration with @OpenAI and @sanofi to transform drug development with AI. By addressing the drug development and clinical trial bottleneck, we can help bring new medicines to patients faster and more efficiently.Today, hours from the opening of #VivaTech, we’re excited to announce our collaboration with @FormationBio & @OpenAI to build first-in-class AI-powered software. Join us at VivaTech for more on our AI innovations. ⤵️
- In Chinese culture, they call it 'eating bitterness,' Kobe Bryant called it Mamba Mentality. Read my thoughts on why we must embrace this mentality this Chinese New Year.
- Thrilled to welcome Mikael Dolsten, MD, PhD, former Chief Scientific Officer and President of Pfizer R&D, to Formation Bio to chair our drug picking efforts. As we look to bring together the best of pharma with the best of AI and technology, we are honored to partner with Mikael
- 1. As AI accelerates drug discovery, our industry will have more potential drug candidates than it can develop because of the high cost and time of drug development.We are excited to announce our collaboration with @OpenAI & @sanofi to build fine-tuned and custom AI solutions to transform drug development, advancing our mission to bring new treatments to patients faster and more efficiently. sanofi.com/en/media-room/…
- After years of running trials for other drugmakers, TrialSpark is building its own pipeline -
